View Financial HealthAequus Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Aequus Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 02Luvo Medical Technologies Inc. completed the acquisition of Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS).Luvo Medical Technologies Inc. signed an asset purchase agreement to acquire Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS) for CAD 0.40 million on May 22, 2025. Under the terms of the agreement, Luvo will pay Aequus a lump sum payment of CAD 0.4 million at the closing of the transaction and an ongoing royalty of 6% on gross profit attributable to the sale of Zimed PF® (less certain costs and fees) until July 29th, 2029. The Transaction is expected to close in Q4 2025 upon the transfer of the Drug Identification Number (DIN) and is subject to certain closing conditions, including TSX Venture Exchange and shareholder approval. Aequus expects to call a special meeting of shareholders to be held in Q3 2025 for approval of the Transaction. As of October 20, 2025, The Transaction is expected to close on or before January 20, 2026. As of November 21, 2025, the transaction was approved by the Aequus shareholders at the Annual General and Special Meeting. Blake, Cassels & Graydon LLP acted as legal advisor for Aequus Pharmaceuticals. McMillan LLP acted as legal advisor for Luvo Medical Technologies. Luvo Medical Technologies Inc. completed the acquisition of Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS) on March 31, 2026.お知らせ • Sep 23Aequus Pharmaceuticals Inc. Appoints Giovanni Di Genova to the Board of Directors, Effective from September 12, 2025Aequus Pharmaceuticals Inc. announced Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective September 12th, 2025. Aequus is pleased to welcome Giovanni Di Genova as a new director and are eager to work with him on the future ahead. Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Universit de Montral, respectively. He began his career in the specialty compounding pharmacy &pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals.お知らせ • Sep 19Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025. Location: british columbia, vancouver Canadaお知らせ • Aug 25Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in CanadaAequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.お知らせ • Aug 19Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in CanadaAequus Pharmaceuticals Inc. announced the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications. Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market. The company look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued. Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon. The Company remains steadfast in its commitment to delivering innovative solutions that enhance the well-being of patients across Canada.お知らせ • May 27Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023.決済の安定と成長配当データの取得安定した配当: AQSZ.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: AQSZ.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Aequus Pharmaceuticals 配当利回り対市場AQSZ.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (AQSZ.F)n/a市場下位25% (US)1.3%市場トップ25% (US)4.1%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (AQSZ.F) (最長3年)n/a注目すべき配当: AQSZ.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: AQSZ.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: AQSZ.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: AQSZ.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/20 16:45終値2026/07/14 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aequus Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Nathan CaliNOBLE Capital Markets, Inc.
お知らせ • Apr 02Luvo Medical Technologies Inc. completed the acquisition of Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS).Luvo Medical Technologies Inc. signed an asset purchase agreement to acquire Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS) for CAD 0.40 million on May 22, 2025. Under the terms of the agreement, Luvo will pay Aequus a lump sum payment of CAD 0.4 million at the closing of the transaction and an ongoing royalty of 6% on gross profit attributable to the sale of Zimed PF® (less certain costs and fees) until July 29th, 2029. The Transaction is expected to close in Q4 2025 upon the transfer of the Drug Identification Number (DIN) and is subject to certain closing conditions, including TSX Venture Exchange and shareholder approval. Aequus expects to call a special meeting of shareholders to be held in Q3 2025 for approval of the Transaction. As of October 20, 2025, The Transaction is expected to close on or before January 20, 2026. As of November 21, 2025, the transaction was approved by the Aequus shareholders at the Annual General and Special Meeting. Blake, Cassels & Graydon LLP acted as legal advisor for Aequus Pharmaceuticals. McMillan LLP acted as legal advisor for Luvo Medical Technologies. Luvo Medical Technologies Inc. completed the acquisition of Zimed® PF from Aequus Pharmaceuticals Inc. (TSXV:AQS) on March 31, 2026.
お知らせ • Sep 23Aequus Pharmaceuticals Inc. Appoints Giovanni Di Genova to the Board of Directors, Effective from September 12, 2025Aequus Pharmaceuticals Inc. announced Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective September 12th, 2025. Aequus is pleased to welcome Giovanni Di Genova as a new director and are eager to work with him on the future ahead. Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Universit de Montral, respectively. He began his career in the specialty compounding pharmacy &pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals.
お知らせ • Sep 19Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025. Location: british columbia, vancouver Canada
お知らせ • Aug 25Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in CanadaAequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
お知らせ • Aug 19Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in CanadaAequus Pharmaceuticals Inc. announced the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications. Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market. The company look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued. Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon. The Company remains steadfast in its commitment to delivering innovative solutions that enhance the well-being of patients across Canada.
お知らせ • May 27Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023.